Home » Authors » Rachelle H.B. Fishman

Articles by Rachelle H.B. Fishman

Israeli Biotech Continues Growth With Private, Government Support

May 7, 2003

By Rachelle H.B. Fishman

Ester Neuroscience Gets Good Results In Early Antisense Trial

April 9, 2003

By Rachelle H.B. Fishman

Chiasma Gets First Biotech Investment From InnoMed

April 9, 2003

By Rachelle H.B. Fishman

Bioline Therapeutics Formed By Israeli Groups With $11M Funding

April 9, 2003

By Rachelle H.B. Fishman

Gamida-Cell, Teva Enter Deal To Develop Stem Cell Product

March 26, 2003

By Rachelle H.B. Fishman

MediWound's Burn Agent Gains Orphan Status, Starts Phase IIb

March 5, 2003

By Rachelle H.B. Fishman

Ester Neuroscience Successfully Delivers Antisense Drug Orally

Jan. 8, 2003

By Rachelle H.B. Fishman

Founders Staying In Israel As Keryx Moves Operations To U.S.

Jan. 1, 2003

By Rachelle H.B. Fishman

Japanese, Israeli Firms Unite On Tyrosine Kinase Blockers

Dec. 11, 2002

By Rachelle H.B. Fishman

Competitors Managing Israel's First Private Biotech Incubators

Dec. 4, 2002

By Rachelle H.B. Fishman

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...